Chung Wu Investment Group LLC acquired a new position in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 7,350 shares of the company's stock, valued at approximately $482,000.
Several other hedge funds and other institutional investors have also bought and sold shares of AZN. Swedbank AB lifted its stake in AstraZeneca by 1.3% in the third quarter. Swedbank AB now owns 2,705,757 shares of the company's stock valued at $210,806,000 after buying an additional 35,000 shares in the last quarter. Harvest Portfolios Group Inc. lifted its stake in AstraZeneca by 3.0% in the third quarter. Harvest Portfolios Group Inc. now owns 728,187 shares of the company's stock valued at $56,733,000 after buying an additional 21,514 shares in the last quarter. Concurrent Investment Advisors LLC lifted its stake in AstraZeneca by 39.6% in the third quarter. Concurrent Investment Advisors LLC now owns 12,685 shares of the company's stock valued at $988,000 after buying an additional 3,597 shares in the last quarter. D.B. Root & Company LLC lifted its stake in AstraZeneca by 4.0% in the third quarter. D.B. Root & Company LLC now owns 8,919 shares of the company's stock valued at $695,000 after buying an additional 345 shares in the last quarter. Finally, Kornitzer Capital Management Inc. KS lifted its stake in AstraZeneca by 0.3% in the third quarter. Kornitzer Capital Management Inc. KS now owns 360,312 shares of the company's stock valued at $28,072,000 after buying an additional 1,031 shares in the last quarter. Institutional investors own 20.35% of the company's stock.
Analyst Ratings Changes
A number of analysts have recently commented on the stock. UBS Group raised shares of AstraZeneca from a "neutral" rating to a "buy" rating in a research report on Thursday, February 13th. Morgan Stanley assumed coverage on shares of AstraZeneca in a research report on Wednesday, February 12th. They issued an "overweight" rating on the stock. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, AstraZeneca currently has an average rating of "Buy" and an average price target of $89.75.
Check Out Our Latest Stock Report on AstraZeneca
AstraZeneca Stock Up 0.0 %
AZN traded up $0.03 during trading on Friday, reaching $77.50. 7,022,104 shares of the stock were exchanged, compared to its average volume of 5,679,263. The stock has a market cap of $240.34 billion, a P/E ratio of 34.29, a price-to-earnings-growth ratio of 1.42 and a beta of 0.41. AstraZeneca PLC has a twelve month low of $62.75 and a twelve month high of $87.68. The stock's 50 day moving average price is $70.83 and its two-hundred day moving average price is $72.74. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.74 and a current ratio of 0.93.
AstraZeneca (NASDAQ:AZN - Get Free Report) last issued its earnings results on Thursday, February 6th. The company reported $1.05 earnings per share for the quarter, missing analysts' consensus estimates of $1.10 by ($0.05). AstraZeneca had a return on equity of 32.23% and a net margin of 13.01%. Equities analysts expect that AstraZeneca PLC will post 4.51 EPS for the current year.
AstraZeneca Increases Dividend
The business also recently disclosed a semi-annual dividend, which will be paid on Monday, March 24th. Shareholders of record on Friday, February 21st will be issued a $1.03 dividend. This is an increase from AstraZeneca's previous semi-annual dividend of $0.49. This represents a dividend yield of 2%. The ex-dividend date is Friday, February 21st. AstraZeneca's payout ratio is currently 91.15%.
AstraZeneca Company Profile
(
Free Report)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Featured Articles
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
